Breakthroughs in molecular profiling applied sciences are enabling a brand new data-intensive strategy to biomedical analysis, with the potential to revolutionize how we examine, handle, and deal with advanced ailments. The following nice problem for scientific functions of those improvements will probably be to create scalable computational options for intelligently linking advanced biomedical affected person knowledge to clinically actionable data.
Conventional database administration techniques (DBMS) are usually not effectively suited to representing advanced syntactic and semantic relationships in unstructured biomedical info, introducing boundaries to realizing such options. We suggest a scalable computational framework for addressing this want, which leverages a hypergraph-based knowledge mannequin and question language which may be higher fitted to representing advanced multi-lateral, multi-scalar, and multi-dimensional relationships. We additionally focus on how this framework can be utilized to create fast studying data base techniques to intelligently seize and relate advanced affected person knowledge to biomedical data with a purpose to automate the restoration of clinically actionable info.
A software program framework for constructing biomedical machine studying classifiers by means of grid computing assets.
This paper describes the BiomedTK software program framework, created to carry out large explorations of machine studying classifiers configurations for biomedical knowledge evaluation over distributed Grid computing assets. BiomedTK integrates ROC evaluation all through the whole classifier development course of and allows explorations of huge parameter sweeps for coaching third celebration classifiers resembling synthetic neural networks and assist vector machines, providing the potential to harness the huge quantity of computing energy serviced by Grid infrastructures.
As well as, it consists of classifiers modified by the authors for ROC optimization and performance to construct ensemble classifiers and manipulate datasets (import/export, extract and rework knowledge, and so forth.). BiomedTK was experimentally validated by coaching 1000’s of classifier configurations for consultant biomedical UCI datasets reaching in little time classification ranges similar to these reported in present literature. The great methodology herewith offered represents an enchancment to biomedical knowledge evaluation in each methodology and potential attain of machine studying based mostly experimentation.
Biomedical cloud computing with Amazon Internet Providers.
On this overview to biomedical computing within the cloud, we mentioned two major methods to make use of the cloud (a single occasion or cluster), supplied an in depth instance utilizing NGS mapping, and highlighted the related prices. Whereas many customers new to the cloud could assume that entry is as simple as importing an software and choosing an occasion sort and storage choices, we illustrated that there’s substantial up-front effort required earlier than an software could make full use of the cloud’s huge assets.
Our intention was to supply a set of greatest practices and as an instance how these apply to a typical software pipeline for biomedical informatics, but additionally common sufficient for extrapolation to different varieties of computational issues. Our mapping instance was supposed as an instance the way to develop a scalable undertaking and to not examine and distinction alignment algorithms for learn mapping and genome meeting.
Certainly, with a more recent aligner resembling Bowtie, it’s potential to map all the African genome utilizing one m2.2xlarge occasion in 48 hours for a complete value of roughly $48 in computation time. In our instance, we weren’t involved with knowledge switch charges, that are closely influenced by the quantity of obtainable bandwidth, connection latency, and community availability.
When transferring massive quantities of knowledge to the cloud, bandwidth limitations is usually a main bottleneck, and in some instances it’s extra environment friendly to easily mail a storage machine containing the info to AWS. Extra details about cloud computing, detailed value evaluation, and safety may be present in references.
Normalized affect issue (NIF): an adjusted methodology for calculating the quotation charge of biomedical journals.
The pursuits in journal affect issue (JIF) in scientific communities have grown over the past a long time. The JIFs are used to judge journals high quality and the papers revealed therein. JIF is a self-discipline particular measure and the comparability between the JIF devoted to totally different disciplines is insufficient, except a normalization course of is carried out.
On this examine, normalized affect issue (NIF) was launched as a comparatively easy methodology enabling the JIFs for use when evaluating the standard of journals and analysis works in several disciplines. The NIF index was established based mostly on the multiplication of JIF by a relentless issue. The constants have been calculated for all 54 disciplines of biomedical discipline throughout 2005, 2006, 2007, 2008 and 2009 years.
Additionally, rating of 393 journals in several biomedical disciplines in accordance with the NIF and JIF have been in comparison with illustrate how the NIF index can be utilized for the analysis of publications in several disciplines. The findings show that the usage of the NIF enhances the equality in assessing the standard of analysis works produced by researchers who work in several disciplines.
DOORS to the semantic net and grid with a PORTAL for biomedical computing.
The semantic net stays within the early levels of growth. It has not but achieved the targets envisioned by its founders as a pervasive net of distributed data and intelligence. Success will probably be attained when a dynamic synergism may be created between folks and a ample variety of infrastructure techniques and instruments for the semantic net in analogy with these for the unique net.
The area title system (DNS), net browsers, and the advantages of publishing net pages motivated many individuals to register domains and publish internet sites on the unique net. An identical useful resource label system, semantic search functions, and the advantages of collaborative semantic networks will encourage folks to register useful resource labels and publish useful resource descriptions on the semantic net.
The Area Ontology Oriented Useful resource System (DOORS) and Downside Oriented Registry of Tags and Labels (PORTAL) are proposed as infrastructure techniques for useful resource metadata inside a paradigm that may function a bridge between the unique net and the semantic net. The Web Registry Data Service (IRIS) registers [corrected] domains whereas DNS publishes area addresses with mapping of names to addresses for the unique net.
 Cyclin D1 antibody |
|||
| 10R-2414 | Fitzgerald | 5 mL | EUR 232.8 |
|
Description: Mouse monoclonal Cyclin D1 antibody |
|||
Cyclin D1 antibody |
|||
| 10R-7849 | Fitzgerald | 100 ug | EUR 484 |
|
Description: Mouse monoclonal Cyclin D1 antibody |
|||
 Cyclin D1 Antibody |
|||
| 47994-100ul | SAB | 100ul | EUR 399.6 |
Cyclin D1 Antibody |
|||
| 47994-50ul | SAB | 50ul | EUR 286.8 |
Cyclin D1 Antibody |
|||
| 48497 | SAB | 100ul | EUR 429 |
Cyclin D1 Antibody |
|||
| 48497-100ul | SAB | 100ul | EUR 399.6 |
Cyclin D1 Antibody |
|||
| 48497-50ul | SAB | 50ul | EUR 286.8 |
Cyclin D1 Antibody |
|||
| 48619 | SAB | 100ul | EUR 529 |
Cyclin D1 Antibody |
|||
| 48619-100ul | SAB | 100ul | EUR 399.6 |
Cyclin D1 Antibody |
|||
| 48619-50ul | SAB | 50ul | EUR 286.8 |
Cyclin D1 Antibody |
|||
| 39315-100ul | SAB | 100ul | EUR 468 |
 Cyclin D1 Antibody |
|||
| E18-0931-1 | EnoGene | 50μg/50μl | EUR 145 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 Antibody |
|||
| E18-0931-2 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 Antibody |
|||
| E18-6234-1 | EnoGene | 50μg/50μl | EUR 145 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 Antibody |
|||
| E18-6234-2 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 Antibody |
|||
| E80407-22 | EnoGene | 100ul 0.5mg/ml | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 Antibody |
|||
| E80407-27 | EnoGene | 100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 Antibody |
|||
| DF6386 | Affbiotech | 200ul | EUR 420 |
Cyclin D1 Antibody |
|||
| DF6386-100ul | Affinity Biosciences | 100ul | EUR 280 |
Cyclin D1 Antibody |
|||
| DF6386-200ul | Affinity Biosciences | 200ul | EUR 350 |
Cyclin D1 Antibody |
|||
| E8RE6024 | EnoGene | 100ul | EUR 275 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 Antibody |
|||
| E300456 | EnoGene | 100ug/200ul | EUR 275 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 Antibody |
|||
| E301101 | EnoGene | 100ug/200ul | EUR 275 |
|
Description: Available in various conjugation types. |
|||
Cyclin D1 antibody |
|||
| CAF50658-100ug | Biomatik Corporation | 100ug | EUR 312 |
Cyclin D1 antibody |
|||
| 70R-13838 | Fitzgerald | 100 ug | EUR 484 |
|
Description: Affinity purified Mouse polyclonal Human Cyclin D1 antibody |
|||
Cyclin D1 antibody |
|||
| 70R-30875 | Fitzgerald | 100 ug | EUR 294 |
|
Description: Rabbit polyclonal Cyclin D1 antibody |
|||
Cyclin D1 antibody |
|||
| 70R-33524 | Fitzgerald | 100 ug | EUR 294 |
|
Description: Rabbit polyclonal Cyclin D1 antibody |
|||
Cyclin D1 Antibody |
|||
| AF0931 | Affbiotech | 200ul | EUR 420 |
Cyclin D1 Antibody |
|||
| AF0931-100ul | Affinity Biosciences | 100ul | EUR 280 |
Cyclin D1 Antibody |
|||
| AF0931-200ul | Affinity Biosciences | 200ul | EUR 350 |
Cyclin D1 Antibody |
|||
| AF6234 | Affbiotech | 200ul | EUR 420 |
Cyclin D1 Antibody |
|||
| AF6234-100ul | Affinity Biosciences | 100ul | EUR 280 |
Cyclin D1 Antibody |
|||
| AF6234-200ul | Affinity Biosciences | 200ul | EUR 350 |
Cyclin D1 Antibody |
|||
| ABD6386 | Nova Lifetech | 100ug | EUR 325 |
Cyclin D1 Antibody |
|||
| ABF0931 | Nova Lifetech | 100ug | EUR 325 |
Cyclin D1 Antibody |
|||
| ABF6234 | Nova Lifetech | 100ug | EUR 325 |
Cyclin D1 Antibody |
|||
| GWB-36F9FE | GenWay Biotech | 0.1 ml | Ask for price |
Cyclin D1 Antibody |
|||
| GWB-412C82 | GenWay Biotech | 0.5 ml | Ask for price |
Cyclin D1 Antibody |
|||
| GWB-182D3C | GenWay Biotech | 0.1 mg | Ask for price |
Cyclin D1 Antibody |
|||
| GWB-1D3C35 | GenWay Biotech | 0.1 ml | Ask for price |
 Cyclin D1, Antibody |
|||
| GWB-A57CFF | GenWay Biotech | 1 ml | Ask for price |
Cyclin D1 Antibody |
|||
| GWB-AA2DFA | GenWay Biotech | 0.05 mg | Ask for price |
Cyclin D1 Antibody |
|||
| GWB-6CFCAA | GenWay Biotech | 0.5 ml | Ask for price |
Cyclin D1 Antibody |
|||
| GWB-7D2D45 | GenWay Biotech | 0.01 mg | Ask for price |
Cyclin D1, Antibody |
|||
| GWB-E16836 | GenWay Biotech | 7 ml | Ask for price |
Cyclin D1, Antibody |
|||
| GWB-E5624D | GenWay Biotech | 1 ml | Ask for price |
Cyclin D1, Antibody |
|||
| GWB-CE0523 | GenWay Biotech | 7 ml | Ask for price |
Cyclin D1, Antibody |
|||
| GWB-DEA75D | GenWay Biotech | 0.1 ml | Ask for price |
Cyclin D1 Antibody |
|||
| R20262-0.1ML | NSJ Bioreagents | 100ul | EUR 347.65 |
|
Description: This recombinant Cyclin D1 antibody reacts to human Cyclin D1. It may also react to the bovine, mouse or rat protein, as predicted by immunogen homology. |
|||
Cyclin D1 Antibody |
|||
| R30348 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: D-type cyclins are regarded as essential links between cell environment and the core cell cycle machinery. Cyclin D1, the product of the human gene CCND1, is also known as BCL1. Cyclin D1 expression is regulated by the retinoblastoma protein. Expression of Cyclin D1, but not of cyclins A and E, was induced by transfection of the RB gene into RB-deficient tumor cells. The CCND1 gene can function as an oncogene. |
|||
Cyclin D1 Antibody |
|||
| R30349 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: Cyclin D1, also known as CCND1, belongs to the highly conserved cyclin family whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. CCND1 encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates the retinoblastoma protein and promotes progression through the G1-S phase of the cell cycle. Amplification or overexpression of the protein plays pivotal roles in the development of a subset of human cancers including parathyroid adenoma, breast cancer, colon cancer, lymphoma, melanoma, and prostate cancer. The gene is overexpressed in breast cancers and is required for oncogene-induced tumorigenesis. Brisken et al. (2003) found that prolactin (PRL; 176760) induced IGF2 (147470) mRNA and IGF2 induced cyclin D1 protein expression in mouse mammary epithelial cultures. They also concluded that IGF2 is a mediator of prolactin-induced alveologenesis and that prolactin, IGF2, and Cyclin D1 are components of a developmental pathway in mammary gland. |
|||
Cyclin D1 Antibody |
|||
| R36266-100UG | NSJ Bioreagents | 100 ug | EUR 339.15 |
|
Description: Additional name(s) for this target protein: CCND1 |
|||
Cyclin D1 Antibody |
|||
| R32025 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: Cyclin D1, also known as CCND1, is a human gene. The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclin D1 encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates the retinoblastoma protein and promotes progression through the G1-S phase of the cell cycle. Amplification or overexpression of cyclin D1 plays pivotal roles in the development of a subset of human cancers including parathyroid adenoma, breast cancer, colon cancer, lymphoma, melanoma, and prostate cancer. The cyclin D1 gene is overexpressed in human breast cancers and is required for oncogene-induced tumorigenesis. Brisken et al. (2003) found that prolactin induced IGF2 mRNA and IGF2 induced cyclin D1 protein expression in mouse mammary epithelial cultures. And they also concluded that IGF2 is a mediator of prolactin-induced alveologenesis and that prolactin, IGF2, and cyclin D1 are components of a developmental pathway in mammary gland. |
|||
Cyclin D1 Antibody |
|||
| MBS9402668-01mL | MyBiosource | 0.1mL | EUR 420 |
Cyclin D1 Antibody |
|||
| MBS9402668-5x01mL | MyBiosource | 5x0.1mL | EUR 1740 |
Cyclin D1 antibody |
|||
| MBS8000589-01mg | MyBiosource | 0.1mg | EUR 515 |
Cyclin D1 antibody |
|||
| MBS8000589-5x01mg | MyBiosource | 5x0.1mg | EUR 1780 |
Cyclin D1 Antibody |
|||
| MBS857444-01mL | MyBiosource | 0.1mL | EUR 310 |
Cyclin D1 Antibody |
|||
| MBS857444-01mLAF350 | MyBiosource | 0.1mL(AF350) | EUR 570 |
Cyclin D1 Antibody |
|||
| MBS857444-01mLAF405 | MyBiosource | 0.1mL(AF405) | EUR 570 |
Cyclin D1 Antibody |
|||
| MBS857444-01mLBiotin | MyBiosource | 0.1mL(Biotin) | EUR 570 |
Cyclin D1 Antibody |
|||
| MBS857444-01mLFITC | MyBiosource | 0.1mL(FITC) | EUR 570 |
Cyclin D1 Antibody |
|||
| MBS857385-01mL | MyBiosource | 0.1mL | EUR 320 |
Cyclin D1 Antibody |
|||
| MBS8564641-01mL | MyBiosource | 0.1mL | EUR 305 |
Cyclin D1 Antibody |
|||
| MBS8564641-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS8564641-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS8564641-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS8564641-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS8564645-01mL | MyBiosource | 0.1mL | EUR 305 |
Cyclin D1 Antibody |
|||
| MBS8564645-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS8564645-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS8564645-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS8564645-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS854598-01mg | MyBiosource | 0.1mg | EUR 345 |
Cyclin D1 Antibody |
|||
| MBS854598-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS854598-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS854598-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS854598-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS8512285-005mg | MyBiosource | 0.05mg | EUR 235 |
Cyclin D1 Antibody |
|||
| MBS8512285-01mg | MyBiosource | 0.1mg | EUR 305 |
Cyclin D1 Antibody |
|||
| MBS8512285-01mLAF405M | MyBiosource | 0.1mL(AF405M) | EUR 465 |
Cyclin D1 Antibody |
|||
| MBS8512285-01mLAF546 | MyBiosource | 0.1mL(AF546) | EUR 465 |
Cyclin D1 Antibody |
|||
| MBS8512285-01mLAF750 | MyBiosource | 0.1mL(AF750) | EUR 465 |
Cyclin D1 Antibody |
|||
| MBS8511166-005mg | MyBiosource | 0.05mg | EUR 235 |
Cyclin D1 Antibody |
|||
| MBS8511166-01mg | MyBiosource | 0.1mg | EUR 305 |
Cyclin D1 Antibody |
|||
| MBS8511166-01mLAF405M | MyBiosource | 0.1mL(AF405M) | EUR 465 |
Cyclin D1 Antibody |
|||
| MBS8511166-01mLAF546 | MyBiosource | 0.1mL(AF546) | EUR 465 |
Cyclin D1 Antibody |
|||
| MBS8511166-01mLAF750 | MyBiosource | 0.1mL(AF750) | EUR 465 |
Cyclin D1 Antibody |
|||
| MBS851751-01mg | MyBiosource | 0.1mg | EUR 345 |
Cyclin D1 Antibody |
|||
| MBS851751-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS851751-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS851751-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Cyclin D1 Antibody |
|||
| MBS851751-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Cyclin D1 antibody |
|||
| MBS226537-01mL | MyBiosource | 0.1mL | EUR 485 |
Cyclin D1 antibody |
|||
| MBS226537-5x01mL | MyBiosource | 5x0.1mL | EUR 2015 |
Cyclin D1 Antibody |
|||
| MBS5312637-01mg | MyBiosource | 0.1mg | EUR 900 |
Cyclin D1 Antibody |
|||
| MBS5312637-5x01mg | MyBiosource | 5x0.1mg | EUR 3905 |
Cyclin D1 antibody |
|||
| MBS5309959-01mg | MyBiosource | 0.1mg | EUR 900 |
Cyclin D1 antibody |
|||
| MBS5309959-5x01mg | MyBiosource | 5x0.1mg | EUR 3905 |
Cyclin D1 Antibody |
|||
| MBS9434867-005mL | MyBiosource | 0.05mL | EUR 325 |
Cyclin D1 Antibody |
|||
| MBS9434867-01mL | MyBiosource | 0.1mL | EUR 445 |
Cyclin D1 Antibody |
|||
| MBS9434867-5x01mL | MyBiosource | 5x0.1mL | EUR 1860 |
Cyclin D1 Antibody |
|||
| MBS9610353-01mL | MyBiosource | 0.1mL | EUR 260 |
Cyclin D1 Antibody |
|||
| MBS9610353-02mL | MyBiosource | 0.2mL | EUR 305 |
Cyclin D1 Antibody |
|||
| MBS9610353-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
Cyclin D1 Antibody |
|||
| MBS9435350-005mL | MyBiosource | 0.05mL | EUR 325 |
Cyclin D1 Antibody |
|||
| MBS9435350-01mL | MyBiosource | 0.1mL | EUR 445 |
Cyclin D1 Antibody |
|||
| MBS9435350-5x01mL | MyBiosource | 5x0.1mL | EUR 1860 |
Cyclin D1 Antibody |
|||
| MBS9435470-005mL | MyBiosource | 0.05mL | EUR 315 |
Cyclin D1 Antibody |
|||
| MBS9435470-01mL | MyBiosource | 0.1mL | EUR 455 |
Cyclin D1 Antibody |
|||
| MBS9435470-5x01mL | MyBiosource | 5x0.1mL | EUR 1910 |
Cyclin D1 Antibody |
|||
| MBS9607043-01mL | MyBiosource | 0.1mL | EUR 260 |
Cyclin D1 Antibody |
|||
| MBS9607043-02mL | MyBiosource | 0.2mL | EUR 305 |
Cyclin D1 Antibody |
|||
| MBS9607043-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
Cyclin D1 Antibody |
|||
| MBS9503530-005mL | MyBiosource | 0.05mL | EUR 285 |
Cyclin D1 Antibody |
|||
| MBS9503530-01mL | MyBiosource | 0.1mL | EUR 385 |
Cyclin D1 Antibody |
|||
| MBS9503530-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
Cyclin D1 Antibody |
|||
| MBS9503834-005mL | MyBiosource | 0.05mL | EUR 285 |
Cyclin D1 Antibody |
|||
| MBS9503834-01mL | MyBiosource | 0.1mL | EUR 385 |
Cyclin D1 Antibody |
|||
| MBS9503834-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
Cyclin D1 Antibody |
|||
| MBS9509357-005mL | MyBiosource | 0.05mL | EUR 285 |
Cyclin D1 Antibody |
|||
| MBS9509357-01mL | MyBiosource | 0.1mL | EUR 385 |
Cyclin D1 Antibody |
|||
| MBS9509357-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
Cyclin D1 Antibody |
|||
| MBS9600609-01mL | MyBiosource | 0.1mL | EUR 260 |
Cyclin D1 Antibody |
|||
| MBS9600609-02mL | MyBiosource | 0.2mL | EUR 305 |
Cyclin D1 Antibody |
|||
| MBS9600609-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
Cyclin D1 Antibody |
|||
| B0417-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: Cyclin D1 Rabbit Polyclonal Antibody |
|||
Cyclin D1 Antibody |
|||
| B0417-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: Cyclin D1 Rabbit Polyclonal Antibody |
|||
Cyclin D1 Antibody |
|||
| B0879-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: Cyclin D1 Rabbit Polyclonal Antibody |
|||
Cyclin D1 Antibody |
|||
| B0879-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: Cyclin D1 Rabbit Polyclonal Antibody |
|||
 anti- Cyclin D1 antibody |
|||
| FNab02124 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against Cyclin D1 |
|||
 Anti- Cyclin D1 antibody |
|||
| MBS177038-01mg | MyBiosource | 0.1mg | EUR 450 |
Anti- Cyclin D1 antibody |
|||
| MBS177038-5x01mg | MyBiosource | 5x0.1mg | EUR 1870 |
) Cyclin D1 antibody (HRP) |
|||
| abx445238-100ug | Abbexa | 100 ug | EUR 678 |
 Cyclin D1 antibody: HRP |
|||
| MBS8000602-01mg | MyBiosource | 0.1mg | EUR 555 |
Cyclin D1 antibody: HRP |
|||
| MBS8000602-5x01mg | MyBiosource | 5x0.1mg | EUR 1965 |
 Cyclin D1 antibody: RPE |
|||
| MBS8000605-01mg | MyBiosource | 0.1mg | EUR 565 |
Cyclin D1 antibody: RPE |
|||
| MBS8000605-5x01mg | MyBiosource | 5x0.1mg | EUR 2005 |
) Cyclin D1 Antibody (S90) |
|||
| MBS9214117-008mL | MyBiosource | 0.08mL | EUR 210 |
Cyclin D1 Antibody (S90) |
|||
| MBS9214117-04mL | MyBiosource | 0.4mL | EUR 430 |
Cyclin D1 Antibody (S90) |
|||
| MBS9214117-5x04mL | MyBiosource | 5x0.4mL | EUR 1910 |
) Cyclin D1 antibody (FITC) |
|||
| abx445237-100ug | Abbexa | 100 ug | EUR 678 |
 Cyclin D1 antibody: FITC |
|||
| MBS8000601-01mg | MyBiosource | 0.1mg | EUR 560 |
Cyclin D1 antibody: FITC |
|||
| MBS8000601-5x01mg | MyBiosource | 5x0.1mg | EUR 1985 |
) Cyclin D1 Antibody (CCND1) |
|||
| F47705-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
|
Description: The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. |
|||
Cyclin D1 Antibody (CCND1) |
|||
| F48111-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
|
Description: CCND1 is the regulatory component of the Cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. CyclinD-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. [UniProt] |
|||
Cyclin D1 Antibody (CCND1) |
|||
| F48111-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 322.15 |
|
Description: CCND1 is the regulatory component of the Cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. CyclinD-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. [UniProt] |
|||
Cyclin D1 Antibody (CCND1) |
|||
| F49118-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
|
Description: CCND1 belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. |
|||
Cyclin D1 Antibody (CCND1) |
|||
| F40063-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
|
Description: CCND1 belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of the gene encoding this protein, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. |
|||
Cyclin D1 Antibody (CCND1) |
|||
| F52187-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
|
Description: Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. Cyclin D1 forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. Mutations, amplification and overexpression of the gene encoding this protein, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. |
|||
 Cyclin D1 Antibody / CCND1 |
|||
| V8651-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Recognizes a protein of 36kDa, identified as cyclin D1. Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. This antibody neutralizes the activity of cyclin D1 in vivo. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of cyclin D1. This antibody is useful in identifying mantle cell lymphomas (cyclin D1 positive) from CLL/SLL and follicular lymphomas (cyclin D1 negative). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express Cyclin D1. |
|||
Cyclin D1 Antibody / CCND1 |
|||
| V8651-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: Recognizes a protein of 36kDa, identified as cyclin D1. Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. This antibody neutralizes the activity of cyclin D1 in vivo. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of cyclin D1. This antibody is useful in identifying mantle cell lymphomas (cyclin D1 positive) from CLL/SLL and follicular lymphomas (cyclin D1 negative). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express Cyclin D1. |
|||
Cyclin D1 Antibody / CCND1 |
|||
| V8651SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Recognizes a protein of 36kDa, identified as cyclin D1. Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. This antibody neutralizes the activity of cyclin D1 in vivo. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of cyclin D1. This antibody is useful in identifying mantle cell lymphomas (cyclin D1 positive) from CLL/SLL and follicular lymphomas (cyclin D1 negative). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express Cyclin D1. |
|||
Cyclin D1 Antibody / CCND1 |
|||
| V8652-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Recognizes a protein of 36kDa, identified as cyclin D1. Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. This antibody neutralizes the activity of cyclin D1 in vivo. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of cyclin D1. This antibody is useful in identifying mantle cell lymphomas (cyclin D1 positive) from CLL/SLL and follicular lymphomas (cyclin D1 negative). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express Cyclin D1. |
|||
Cyclin D1 Antibody / CCND1 |
|||
| V8652-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: Recognizes a protein of 36kDa, identified as cyclin D1. Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. This antibody neutralizes the activity of cyclin D1 in vivo. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of cyclin D1. This antibody is useful in identifying mantle cell lymphomas (cyclin D1 positive) from CLL/SLL and follicular lymphomas (cyclin D1 negative). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express Cyclin D1. |
|||
Cyclin D1 Antibody / CCND1 |
|||
| V8652SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Recognizes a protein of 36kDa, identified as cyclin D1. Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. This antibody neutralizes the activity of cyclin D1 in vivo. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of cyclin D1. This antibody is useful in identifying mantle cell lymphomas (cyclin D1 positive) from CLL/SLL and follicular lymphomas (cyclin D1 negative). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express Cyclin D1. |
|||
Cyclin D1 Antibody / CCND1 |
|||
| V9073-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
|
Description: Cyclin D1 (CCND1), one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of Cyclin D1. This antibody is useful in identifying mantle cell lymphomas (CCND1+) from CLL/SLL and follicular lymphomas (CCND1-). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express CCND1. |
|||
Cyclin D1 Antibody / CCND1 |
|||
| V9073-20UG | NSJ Bioreagents | 20 ug | EUR 186.15 |
|
Description: Cyclin D1 (CCND1), one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of Cyclin D1. This antibody is useful in identifying mantle cell lymphomas (CCND1+) from CLL/SLL and follicular lymphomas (CCND1-). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express CCND1. |
|||
Cyclin D1 Antibody / CCND1 |
|||
| V9073IHC-7ML | NSJ Bioreagents | 7 ml | EUR 424.15 |
|
Description: Cyclin D1 (CCND1), one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of Cyclin D1. This antibody is useful in identifying mantle cell lymphomas (CCND1+) from CLL/SLL and follicular lymphomas (CCND1-). Occasionally, hairy cell leukemia and plasma cell myeloma weakly express CCND1. |
|||
Analogously, PORTAL registers useful resource labels and tags whereas DOORS publishes useful resource places and descriptions with mapping of labels to places for the semantic net. BioPORT is proposed as a prototype PORTAL registry particular for the issue area of biomedical computing.